DONATE

IBEC signs an agreement for 1.5 million euros with Scranton Enterprises

The Institute for Bioengineering of Catalonia (IBEC) has signed an agreement for an initial investment round of one and a half million euros with Scranton Entreprises B.V. -an investment association headquartered in the Netherlands-, with the aim of developing technology that predicts the probability of implantation of embryos obtained through in vitro fertilization.

This agreement is the first to be established within the framework of the institute’s new initiative, the Open Innovation Lab, that offers companies and investors a platform to bring the cutting-edge research to patients and to the market faster.

Deciphering cell language

New insights into the intercellular communications mechanism that regulates cell repositioning leads the way towards the development of targeted therapies in regenerative medicine

Understanding the language of cells in order to redirect them when necessary: this is one possibility unveiled by researchers at the Center for Regenerative Medicine of Barcelona (CMR[B]), led by Dr. Samuel Ojosnegros, who describe in their latest paper the intercellular communications mechanism involved in cell relocation.

The work, published in Proceedings of the National Academy of Sciences (PNAS), was carried out in collaboration with the groups of Elena Martínez (IBEC) and Melike Lakadamyali (ICFO), among others. The fruitful collaboration also gave rise to the publication of work by Verónica Hortigüela, former PhD student in Elena’s group, who bioengineered a nanopatterning strategy that provides control over this communication mechanism.